Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.

Valgimigli, Marco; Frigoli, Enrico; Vranckx, Pascal; Ozaki, Yukio; Morice, Marie-Claude; Chevalier, Bernard; Onuma, Yoshinobu; Windecker, Stephan; Delorme, Laurent; Kala, Petr; Kedev, Sasko; Abhaichand, Rajpal K; Velchev, Vasil; Dewilde, Willem; Podolec, Jakub; Leibundgut, Gregor; Topic, Dragan; Schultz, Carl; Stankovic, Goran; Lee, Astin; ... (2022). Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 80(8), pp. 766-778. Elsevier 10.1016/j.jacc.2022.04.065

Text 1-s2.0-S0735109722053827-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (915kB) | Request a copy

BACKGROUND

Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is common, even in clinical trials.

OBJECTIVES

The purpose of this study was to investigate the impact of nonadherence to study protocol regimens in the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen) trial.

METHODS

At 1-month after PCI, 4,579 high bleeding risk patients were randomized to single antiplatelet therapy (SAPT) for 11 months (or 5 months in patients on oral anticoagulation [OAC]) or dual antiplatelet therapy (DAPT) for ≥2 months followed by SAPT. Coprimary outcomes included net adverse clinical events (NACE), major adverse cardiac and cerebral events (MACE), and major or clinically relevant nonmajor bleeding (MCB) at 335 days. Inverse probability-of-censoring weights were used to correct for nonadherence Academic Research Consortium type 2 or 3.

RESULTS

In total, 464 (20.2%) patients in the abbreviated-treatment and 214 (9.4%) in the standard-treatment groups incurred nonadherence Academic Research Consortium type 2 or 3. At inverse probability-of-censoring weights analyses, NACE (HR: 1.01; 95% CI: 0.88-1.27) or MACE (HR: 1.07; 95% CI: 0.83-1.40) did not differ, and MCB was lower with abbreviated compared with standard treatment (HR: 0.51; 95% CI: 0.60-0.73) consistently across OAC subgroups; among OAC patients, SAPT discontinuation 6 months after PCI was associated with similar MACE and lower MCB (HR: 0.47; 95% CI: 0.22-0.99) compared with SAPT continuation.

CONCLUSIONS

In the MASTER DAPT adherent population, 1-month compared with ≥3-month DAPT was associated with similar NACE or MACE and lower MCB. Among OAC patients, SAPT discontinuation after 6 months was associated with similar MACE and lower MCB than SAPT continuation (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).

Interest & Impact

Downloads

2 since deposited on 19 Aug 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item